Health Trials

Relapsed B Cell Non Hodgkin Lymphoma

4

Review clinical trials related to Relapsed B Cell Non Hodgkin Lymphoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin, glofitamab, or mosunetuzumab, and to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) for the combinations.

Participants needed: 200
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: ADC Therapeutics S.A.Updated: Jun 9, 2026Locations: 42
Eligibility criteria

Male or female participant aged 18 years or older [+23]

Known history of hypersensitivity resulting in treatment discontinuation to or p... [+30]

Read more
Status: Recruiting

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: ImmunityBio, Inc.Updated: May 4, 2026Locations: 2
Eligibility criteria

Have completed ≥2 lines of cytotoxic chemotherapy. [+2]

Histologically documented primary CNS lymphoma, CLL, Burkitt, Burkitt-like lymph... [+25]

Read more
Status: Not yet recruiting

Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

Open-Label, Phase 2 Chemotherapy-Free Study ofCD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.

Participants needed: 20
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: ImmunityBio, Inc.Updated: Mar 17, 2026
Eligibility criteria

Age ≥ 18 to ≤ 75 years old. [+8]

Histologically documented large B-cell lymphomas (eg, diffuse large B-cell lymph... [+24]

Read more
Status: Recruiting

A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

This is a prospective, single-arm, open-label, exploratory clinical study of LUCAR-20SP in adult subjects with relapsed/refractory B-cell non-Hodgkin lymphoma.

Participants needed: 42
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Peking University Cancer Hospital & InstituteUpdated: Mar 25, 2025Locations: 3
Eligibility criteria

Subjects voluntarily participate in clinical research; [+7]

Prior antitumor therapy with insufficient washout period. [+7]

Read more